(Q28266069)

6

0 references

Werner Kissling

5

0 references

author name string

Magdolna Tardy

2

0 references

Katja Komossa

3

0 references

Stephan Heres

4

0 references

John M Davis

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder

7

0 references

language of work or name

English

0 references

publication date

2 June 2012

0 references

published in

The Lancet

0 references

volume

379

0 references

issue

9831

0 references

page(s)

2063-71

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Neuroleptic withdrawal in schizophrenic patients. A review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Overview: maintenance therapy in psychiatry: I. Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Atypical antipsychotic drugs and the risk of sudden cardiac death

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

International consensus study of antipsychotic dosing.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Trial of Maintenance Therapy in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Confidence intervals for the number needed to treat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Schizophrenics Fully Remitted on Neuroleptics for 3–5 years—To Stop or Continue Drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

A randomised controlled trial of prophylactic neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

DISCONTINUATION OR REDUCTION OF CHEMOTHERAPY IN CHRONIC SCHIZOPHRENICS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Prophylactic effect of neuroleptics in symptom-free schizophrenics.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Differential effects of abrupt versus gradual withdrawal of chlorpromazine in hospitalized chronic schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Depot antipsychotic drugs. Place in therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960239-6

7 January 2021

10.1016/S0140-6736(12)60239-6

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

22560607

1 reference

Consolidated OpenCitations Corpus – April 2017